Skip to content
All Podcasts – Lifestyle
Author:
AgomAb Therapeutics N.V.
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026
←
Previous Page
1
2